Indian companies created over 100,000 jobs in the US in recent months, which will define the relationship into the New Year.
Biocon widens BristolMyers Squibb tie-up
Biocon’s contract research arm, Syngene International, has expanded its ongoing drug discovery and development with US-based Bristol-Myers Squibb till 2026.
Syngene International said in a Bombay Stock Exchange (BSE) filing: “The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026.”
The expansion will enable the two companies to undertake a greater range of scientific research and development for pharmaceuticals across a broader range of activities.
Syngene’s new dedicated facility will be spread across 25,000 sq ft of laboratory and office space for Bristol-Myers Squibb. It will house an additional team of 75 Syngene scientists who will work exclusively for Bristol-Myers Squibb.
Biocon BMS Research Center (BBRC), Syngene’s first dedicated R&D centre, was established in 2007, which was subsequently renewed through 2020 and now has been extended till 2026.
It is the largest research and development facility for Bristol-Myers Squibb outside the United States and plays an integral part within their global research and development network.